Relative risk for TB among PSL-treated biologic-naïve patients with RA.
| Treatment With PSL* | TB Cases, n = 23 | Controls, n = 63 | aOR** (95% CI) |
|---|---|---|---|
| Maximum dose, mg | 14.1 ± 10.8 (5–50)a | 11 ± 9.1 (2.5–40)a | 1.04 (0.98–1.10) |
| Duration of treatment, weeks | 306 ± 361 (7–1426)a | 297 ± 324 (4–1265)b | 1.0 (1.0–1.0) |
| Cumulative dose the last year before TB diagnosis, mg, mean ± SD (min-max) [n] | 2153 ± 888 (280–3600)a [14] | 1769 ± 784 (225–3650)c [42] | 1.00 (1.00–1.00) |
| ≥ 15 mg/d PSL ≥ 1 month ever before TB diagnosis, n (%) | 3 (10) | 7 (5.7) | 0.9 (0.1–8.3) |
| ≥ 15 mg/d PSL ≥ 1 month the last year before TB diagnosis, n (%)a | 2 (6.5) | 1 (0.8) | NA |
| Mean daily dose 1 year before TB diagnosis, mg [n] | 5.78 [14]d | 5.66 [40]d | 1.0 (0.8–1.2) |
| Mean daily dose at TB diagnosis, mg [n] | 8.23 [16]d | 5.12 [41] | 1.2 (1.05–1.5) |
Values are expressed as mean ± SD (min-max) unless stated otherwise.
↵a Missing data from 3 patients.
↵b Missing data from 9 patients.
↵c Missing data from 14 patients.
↵d Missing data from 2 patients.
↵* Treatment for ≥ 4 consecutive weeks from RA diagnosis until TB diagnosis.
↵** Estimated from logistic regression models adjusted for sex, age, and DMARD medication.
aOR: adjusted OR; DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis; PSL: prednisolone; TB: tuberculosis.